RxDoctor Payments Data

Paula Villarejo, MD

Internal Medicine · Columbus, INNPI 1144516642

Payments from drug & device makers

$9,159in general payments, 2019–2025

Across 544 payments — averaging $16.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$764
  • Pfizer$475
  • Bayer$424
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$8,98098%
  • Education$1792%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,159 in reported general payments places this provider in the 90th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$64,688
Medicare patients
208
Services billed
676

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin55$81,736
EliquisApixaban56$69,530
OzempicSemaglutide35$50,350
FarxigaDapagliflozin Propanediol46$45,332
TrulicityDulaglutide26$42,874
MounjaroTirzepatide17$30,781
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$27,164
JanuviaSitagliptin Phosphate15$17,643
XareltoRivaroxaban14$16,869
RybelsusSemaglutide11$15,807
Tresiba Flextouch U-100Insulin Degludec13$10,755
MyrbetriqMirabegron11$8,433
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$6,721
SymbicortBudesonide/Formoterol Fumarate15$6,357
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$4,387

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$235$81,73655 claims
Lilly USA, LLCTrulicity, Mounjaro$764$73,65643 claims
PfizerEliquis, Paxlovid$475$70,95976 claims
Novo NordiskOzempic, Rybelsus$1,054$66,15846 claims
AstraZenecaFarxiga, Symbicort$1,430$51,69061 claims
GSKTrelegy Ellipta, Anoro Ellipta$313$33,88538 claims
MerckJanuvia$96$17,64315 claims
Johnson & JohnsonXarelto$60$16,86914 claims
Astellas Pharma US IncMyrbetriq$345$8,43311 claims
AbbVieSynthroid$1,890$1,36226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Columbus

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →